Genentech has completed its FDA submission of a supplemental Biologics License Application for ado-trastuzumab emtansine as an adjuvant treatment for patients with HER2-positive early breast cancer who had residual disease following neoadjuvant therapy.
Original Article: FDA Approval Sought for Adjuvant T-DM1 in High-Risk HER2+ Breast Cancer